What type of study is this?

This is a In Vitro Study study.

December 8, 2025Blood

Comparison of hemostatic dosing of factor IX wild-type and padua (R338L) in multiple hemophilia B mouse models

View Full Paper

Ask AI

Bookmark

Hemostasis improves significantly with FIX-Padua, highlighting its potential for clinical applications.
Factor IX (FIX) Padua variant shows 4-6 fold increased potency compared to FIX-WT in mouse models.
Recombinant FIX-Padua demonstrates lower EC50 values than FIX-WT, indicating higher efficacy.
Gene therapy with FIX-Padua supports ongoing advancements in hemophilia B treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis indicates increased hemostatic potency of FIX-Padua over FIX-WT in hemophilia B mice, suggesting potential therapeutic advantages.

Cite This Study

Ben Samelson-Jones (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0fc https://doi.org/10.1182/blood-2025-4831

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis indicates increased hemostatic potency of FIX-Padua over FIX-WT in hemophilia B mice, suggesting potential therapeutic advantages.

Comparison of hemostatic dosing of factor IX wild-type and padua (R338L) in multiple hemophilia B mouse models

Key Points

Discussion

Implication

Cite This Study

Comparison of hemostatic dosing of factor IX wild-type and padua (R338L) in multiple hemophilia B mouse models

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider